| __timestamp | Neurocrine Biosciences, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 46425000 | 47795223 |
| Thursday, January 1, 2015 | 81491000 | 50426000 |
| Friday, January 1, 2016 | 94291000 | 70853000 |
| Sunday, January 1, 2017 | 121827000 | 78168000 |
| Monday, January 1, 2018 | 160524000 | 123757000 |
| Tuesday, January 1, 2019 | 200000000 | 140963000 |
| Wednesday, January 1, 2020 | 275000000 | 131773000 |
| Friday, January 1, 2021 | 328100000 | 210328000 |
| Saturday, January 1, 2022 | 463800000 | 235780000 |
| Sunday, January 1, 2023 | 565000000 | 244990000 |
| Monday, January 1, 2024 | 731100000 |
Data in motion
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc. have demonstrated contrasting trajectories in their R&D investments.
From 2014 to 2023, Neurocrine Biosciences increased its R&D budget by over 1,100%, reflecting a robust growth strategy aimed at expanding its therapeutic portfolio. In contrast, Travere Therapeutics saw a more modest increase of approximately 410% during the same period. By 2023, Neurocrine's R&D expenses were more than double those of Travere, highlighting its aggressive pursuit of new drug development.
This trend underscores the varying strategic priorities within the biotech sector, where some companies prioritize rapid innovation while others adopt a more measured approach.
Analyzing R&D Budgets: Merck & Co., Inc. vs Neurocrine Biosciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for AstraZeneca PLC and Neurocrine Biosciences, Inc.
Research and Development Expenses Breakdown: Pfizer Inc. vs Neurocrine Biosciences, Inc.
Analyzing R&D Budgets: GSK plc vs Travere Therapeutics, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Travere Therapeutics, Inc.
Research and Development Investment: Neurocrine Biosciences, Inc. vs Exelixis, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and Grifols, S.A. Allocate Funds
R&D Insights: How Neurocrine Biosciences, Inc. and Alpine Immune Sciences, Inc. Allocate Funds
Research and Development Investment: Neurocrine Biosciences, Inc. vs Celldex Therapeutics, Inc.
Research and Development Investment: Sarepta Therapeutics, Inc. vs Travere Therapeutics, Inc.
R&D Insights: How Halozyme Therapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds
R&D Insights: How Iovance Biotherapeutics, Inc. and Travere Therapeutics, Inc. Allocate Funds